+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Therapeutic Vaccines Market Distribution by Type of Vaccine, Method of Vaccine Composition, Type of Therapy, Target Disease Indication, Route of Administration and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035

  • PDF Icon

    Report

  • 365 Pages
  • May 2022
  • Region: Global
  • Roots Analysis
  • ID: 5583909
Description Jump to:
Unlike the prophylactic vaccines that are designed and administered as a precautionary measure to prevent the occurrence of a disease, researchers have developed therapeutic vaccines intended to alleviate the suffering of patients already infected with the disease. Therapeutic vaccines are not as efficacious as prophylactic vaccines; however, they demonstrate safety, specificity and a long-lasting response across various clinical conditions. These vaccines help the immune system in recognizing a foreign agent and are primarily being developed for viral infections and different types of cancer. Additionally, individuals who are affected with chronic infections but cannot produce enough efficient antibodies can be administered such vaccines. Currently, six therapeutic vaccines are commercially available, including Imlygic®, Provenge® and Tice® which have recently been approved for treatment of melanoma, prostate cancer and bladder cancer, respectively; in addition, over 350 vaccines are under development for various oncological, infectious, hepatological, neurological and autoimmune disorders. 
 
Extensive research is being conducted to improve the overall stability of these therapeutic formulations and a variety of adjuvants (substances with an innate potential to augment an immune response) have been discovered for the development of more versatile vaccine formulations. Further, researchers are also investigating the potential of these vaccines against other chronic disease conditions, including hypertension and autoimmune disorders. Over the last few years, this segment of industry has witnessed substantial partnership activity and investment from various private and public sector investors/investment funds, which have extended financial support to the organizations engaged in R&D. Driven by encouraging clinical trial results, increasing adoption of therapeutic vaccines for treating various clinical conditions and investment in R&D, the therapeutic vaccines market is poised to witness noteworthy growth in the foreseen future.

Scope of the Report

The “Global Therapeutic Vaccines Market, 2022–2035” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution and future opportunities associated with the therapeutic vaccines market. The study underlines an in-depth analysis, highlighting the key drivers and the market trends related to this evolving segment of the pharmaceutical industry. Amongst other elements, the report includes:

  • A detailed assessment of the current market landscape of therapeutic vaccines, based on several relevant parameters, such as phase of development (clinical and preclinical) of lead candidates, type of vaccine (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), type of vaccine by method of composition (autologous vaccine and allogeneic vaccine), type of therapy (monotherapy and combination therapy), target disease indication and route of administration (intramuscular, intranasal, oral, intradermal, subcutaneous, intravenous and others) and dosing frequency. It also includes a list of players developing therapeutic vaccines along with information on their year of establishment, company size and location of headquarters.
  • Elaborate profiles of key players engaged in the development of therapeutic vaccines, based across North America, Europe and Asia Pacific. Each profile features a brief overview of the company, its financial information (if available), details on its clinical-stage vaccine candidates, recent developments and an informed future outlook.
  • A detailed analysis of completed, ongoing and planned clinical trials of various therapeutic vaccines, based on important parameters, such as trial registration year, phase of development, trial recruitment status, study design, trial focus area, target disease indication(s), type of sponsor / collaborator, leading industry sponsors / collaborators (in terms of number of trials conducted), number of patients enrolled and regional distribution.
  • An in-depth analysis of grants that have been awarded to various research institutes for research related to therapeutic vaccines, during the period, 2016-2022, on the basis of different parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, type of recipient organization and focus area. In addition, it highlights the geographical distribution of recipient organizations, popular NIH departments, prominent program officers, and popular recipient organizations.  
  • An analysis of the partnerships that have been established in this domain since 2016, covering instances of product development and / or commercialization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, clinical trial agreements, and other relevant deals. 
  • An analysis of the various start-ups engaged in the field of therapeutic vaccines, based on relevant parameters, such as number of candidates in discovery, preclinical and clinical phases of development, amount raised in different funding instances and number of partnerships established.
  • A case study on preventive vaccines, along with information on marketed as well as clinical-stage candidates, based on parameters, such as phase of development, route of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others), type of vaccine API (live attenuated vaccine, inactivated vaccine, conjugate vaccine, subunit vaccine, toxoid vaccine and others), dosage form (ready to use liquid, lyophilized powder, nasal spray, capsule, and tablet) and target disease indication.
  • A case study on contract manufacturing for vaccines, featuring a comprehensive list of active CMOs and analyses based on a number of parameters, such as year of establishment, company size, scale of operation (preclinical, clinical and commercial), geographical location, number of vaccine manufacturing facilities, types of services offered (cell / virus banking, analytical development / testing, formulation, process development, fill / finish and regulatory filings), type of expression systems used for vaccine production (mammalian, microbial and others) and type of vaccine manufactured.

One of the key objectives of the report was to estimate the existing market size and future growth opportunity associated with therapeutic vaccines market in the mid to long term. Based on parameters, such as adoption rates and expected prices variations for these products, the publisher has developed informed estimates on the likely evolution of the market for the period 2022-2035.

Our year-wise projections of the current and forecasted opportunity within the therapeutic vaccines market, have further been segmented across different types of vaccines (antigen vaccine, dendritic vaccine, DNA vaccine and peptide vaccine), types of vaccines by method of composition (autologous and allogeneic vaccine), types of therapies (monotherapy and combination), target disease indications, routes of administration (intramuscular, subcutaneous, oral, intranasal, intradermal and others) and key geographical regions (North America, Europe and Asia Pacific).

In order to account for future uncertainties and to add robustness to their model, the publisher has provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.  

The opinions and insights presented in the report were influenced by discussions held with senior representatives in the industry. All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD unless otherwise specified.

Key Questions Answered

  • Who are the leading industry players involved in developing therapeutic vaccines?
  • What are the key therapeutic areas for which therapeutic vaccines are being / have been developed?
  • What are the prevalent trends within competitive landscape of therapeutic vaccines?
  • Which geographies are the most active in conducting clinical trials related to therapeutic vaccines?
  • Which are the leading funding organizations providing grants for therapeutic vaccines?
  • What kind of partnership models are commonly adopted by industry and non-industry stakeholders?
  • What are the different initiatives undertaken by start-up players for the development of therapeutic vaccines in the recent past?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Introduction to Therapeutic Vaccines
3.2.1. Classification of Vaccines by Method of Composition
3.2.1.1. Autologous Vaccines
3.2.1.2. Allogeneic Vaccines
3.3. Classification of Vaccines by Mechanism of Action
3.3.1. Antigen Vaccines
3.3.2. Dendritic Vaccines
3.3.3. DNA Vaccines
3.3.4. Peptide Vaccines
3.4 Key Target Indications
3.4.1. Cancer
3.4.2. HIV Infection
3.4.3. HPV Infection
3.4.4. Herpes
3.5. Clinical Development and Approval of Vaccines
3.6. Concluding Remarks
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Therapeutic Vaccines: Pipeline Analysis
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Vaccine
4.2.3. Analysis by Type of Vaccine (by Method of Composition)
4.2.4. Analysis by Type of Therapy
4.2.5. Analysis by Target Disease Indication
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Dosage
4.3. Therapeutic Vaccines: Analysis by Vaccine Developers
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Leading Developers
4.3.5. Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. BioNTech
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Therapeutic Vaccines Portfolio
5.2.4. Recent Developments and Future Outlook
5.3 Brii Biosciences
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Therapeutic Vaccines Portfolio
5.3.4. Recent Developments and Future Outlook
5.4 GlobeImmune
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Therapeutic Vaccines Portfolio
5.4.4. Recent Developments and Future Outlook
5.5 Immatics
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Therapeutic Vaccines Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Immune Response Biopharma
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Therapeutic Vaccines Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. Immunitor
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Therapeutic Vaccines Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Inovio Pharmaceuticals
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Therapeutic Vaccines Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. Moderna
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Therapeutic Vaccines Portfolio
5.9.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. Therapeutic Vaccines: Clinical Trial Analysis
6.3.1. Analysis by Trial Registration Year
6.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
6.3.3. Analysis by Trial Phase
6.3.4. Analysis by Trial Recruitment Status
6.3.5. Analysis by Study Design
6.3.6. Analysis by Trial Focus Area
6.3.7. Analysis by Target Disease Indication
6.3.8. Analysis by Type of Sponsor / Collaborator
6.3.9. Most Active Players: Analysis by Number of Registered Trials
6.3.10. Geographical Analysis by Number of Registered Trials
6.3.11. Geographical Analysis by Enrolled Patient Population
7. ACADEMIC GRANT ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Therapeutic Vaccines: Academic Grant Analysis
7.3.1. Analysis by Year of Grant Award
7.3.2. Analysis by Amount Awarded
7.3.3. Analysis by Administering Institute Center
7.3.4. Analysis by Support Period
7.3.5. Analysis by Administering Institute Center and Support Period
7.3.6. Analysis by Type of Grant Application
7.3.7. Analysis by Purpose of Grant Award
7.3.8. Analysis by Activity Code
7.3.9. Analysis by Study Section Involved
7.3.10. Analysis by Type of Recipient Organization
7.3.11. Word Cloud Analysis: Emerging Focus Areas
7.3.12. Geographical Distribution of Recipient Organizations
7.3.13. Popular NIH Departments: Analysis by Number of Grants
7.3.14. Prominent Program Officers: Analysis by Number of Grants
7.3.15. Popular Recipient Organizations: Analysis by Number of Grants
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Therapeutic Vaccines: Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Year of Partnership and Type of Partner
8.3.4. Analysis by Type of Partnership and Type of Partner
8.3.5. Analysis by Focus Area
8.3.6. Analysis by Therapeutic Area
8.3.7. Most Active Players: Analysis by Number of Partnerships
8.3.8. Regional Analysis
8.3.8.1. Intercontinental and Intracontinental Agreements
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups in Therapeutic Vaccines Market
9.2.1. Analysis by Location of Headquarters
9.3. Benchmarking of Start-ups
9.3.1. Analysis by Supplier Strength
9.3.2. Analysis by Pipeline Strength
9.3.3. Analysis by Pipeline Maturity
9.3.4. Analysis by Financial Investment
9.3.5. Analysis by Partnership Activity
9.3.6. Start-ups Health Indexing: Publisher Analysis Perspective
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Global Therapeutic Vaccines Market, 2022-2035
10.4. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Vaccine
10.5. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Method of Vaccine Composition
10.6. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Type of Therapy
10.7. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Target Disease Indication
10.8. Global Therapeutic Vaccines Market, 2022-2035: Distribution by Route of Administration
10.9. Global Therapeutic Vaccines Market, 2022-2035: Geographical Distribution
10.9.1. Therapeutic Vaccines Market in US, 2022-2035
10.9.2. Therapeutic Vaccines Market in Canada, 2022-2035
10.9.3. Therapeutic Vaccines Market in UK, 2022-2035
10.9.4. Therapeutic Vaccines Market in Germany, 2022-2035
10.9.5. Therapeutic Vaccines Market in France, 2022-2035
10.9.6. Therapeutic Vaccines Market in Italy, 2022-2035
10.9.7. Therapeutic Vaccines Market in Spain, 2022-2035
10.9.8. Therapeutic Vaccines Market in Australia, 2022-2035
10.9.9. Therapeutic Vaccines Market in Japan, 2022-2035
10.9.10. Therapeutic Vaccines Market in Korea, 2022-2035
10.9.11. Therapeutic Vaccines Market in Brazil, 2022-2035
10.9.12. Therapeutic Vaccines Market in Israel, 2022-2035
10.10. Global Therapeutic Vaccines Market, 2022-2035: Individual Product Sales Forecast
10.10.1. ASP0113
10.10.1.1. Target Patient Population
10.10.1.2. Sales Forecast
10.10.2. Copaxone
10.10.2.1. Target Patient Population
10.10.2.2. Sales Forecast
10.10.3. Galinpepimut-S
10.10.3.1. Target Patient Population
10.10.3.2. Sales Forecast
10.10.4. Hepcortespenlisimut-L
10.10.4.1. Target Patient Population
10.10.4.2. Sales Forecast
10.10.5. ICT-107
10.10.5.1. Target Patient Population
10.10.5.2. Sales Forecast
10.10.6. IR103
10.10.6.1. Target Patient Population
10.10.6.2. Sales Forecast
10.10.7. MGN1703
10.10.7.1. Target Patient Population
10.10.7.2. Sales Forecast
10.10.8. Neuronata-R
10.10.8.1. Target Patient Population
10.10.8.2. Sales Forecast
10.10.9. OncoVax
10.10.9.1. Target Patient Population
10.10.9.2. Sales Forecast
10.10.10. OSE2101
10.10.10.1. Target Patient Population
10.10.10.2. Sales Forecast
10.10.11. Provenge
10.10.11.1. Target Patient Population
10.10.11.2. Sales Forecast
10.10.12. REMUNE
10.10.12.1. Target Patient Population
10.10.12.2. Sales Forecast
10.10.13. RIAVAX
10.10.13.1. Target Patient Population
10.10.13.2. Sales Forecast
10.10.14. V503
10.10.14.1. Target Patient Population
10.10.14.2. Sales Forecast
10.10.15. V7
10.10.15.1. Target Patient Population
10.10.15.2. Sales Forecast
10.10.16. VGX-3100
10.10.16.1. Target Patient Population
10.10.16.2. Sales Forecast
10.10.17. Vigil
10.10.17.1. Target Patient Population
10.10.17.2. Sales Forecast
11. CASE STUDY: GLOBAL PREVENTIVE VACCINES
11.1. Chapter Overview
11.2. Preventive Vaccines: Overall Market Landscape
11.2.1. Marketed Vaccines Landscape
11.2.2. Clinical-Stage Vaccines Landscape
11.2.3. Analysis by Phase of Development
11.2.4. Analysis by Route of Administration
11.2.5. Analysis by Type of Vaccine API
11.2.6. Analysis by Dosage Form
11.2.7. Analysis by Target Disease Indication
11.2.8. Key Industry Players: Analysis by Number of Vaccines in Clinical Development
11.2.9. Key Non-Industry Players: Analysis by Number of Vaccines in Clinical Development
12. CASE STUDY: VACCINE CONTRACT MANUFACTURING MARKET
12.1 Chapter Overview
12.2. Vaccine Contract Manufacturers: Overall Market Landscape
12.2.1 Analysis by Year of Establishment
12.2.2. Analysis by Company Size and Geographical Location
12.2.3. Analysis by Geography
12.2.4. Analysis by Type of Service(s) Offered
12.2.5. Analysis by Scale of Operation
12.2.6. Analysis by Type of Expression System(s) Used
12.2.7. Analysis by Type of Vaccines Manufactured
13. CONCLUDING REMARKS14. APPENDIX 1: TABULATED DATA15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Difference between Preventive Vaccines and Therapeutic Vaccines
Figure 3.2 Different Routes of Vaccine Administration
Figure 4.1 Therapeutic Vaccines: Distribution by Phase of Development
Figure 4.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Figure 4.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Figure 4.4 Therapeutic Vaccines: Distribution by Type of Therapy
Figure 4.5 Therapeutic Vaccines: Distribution by Target Disease Indication
Figure 4.6 Therapeutic Vaccines: Distribution by Route of Administration
Figure 4.7 Therapeutic Vaccines: Distribution by Dosage
Figure 4.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Figure 4.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Figure 4.10 Therapeutic Vaccines Developers: Distribution by Company Size
Figure 4.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Figure 4.12 Leading Developers
Figure 4.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Figure 5.1 BioNTech: Annual Revenues, 2016-2021 (USD Million)
Figure 5.2 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
Figure 5.3 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
Figure 5.4 Immatics: Annual Revenues, 2016-2021 (USD Million)
Figure 5.5 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
Figure 5.6 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
Figure 5.7 Moderna: Annual Revenues, 2016-2021 (USD Million)
Figure 6.1 Clinical Trial Analysis: Scope and Methodology
Figure 6.2 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Figure 6.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
Figure 6.4 Clinical Trial Analysis: Distribution by Trial Phase
Figure 6.5 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 6.6 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Figure 6.7 Clinical Trial Analysis: Distribution by Study Design
Figure 6.8 Clinical Trial Analysis: Distribution by Trial Focus Area
Figure 6.9 Clinical Trial Analysis: Distribution by Target Disease Indication
Figure 6.10 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 6.11 Most Active Players: Distribution by Number of Registered Trials
Figure 6.12 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 6.13 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.1 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
Figure 7.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
Figure 7.3 Grant Analysis: Distribution by Administering Institute Center
Figure 7.4 Grant Analysis: Distribution by Support Period
Figure 7.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 7.6 Grant Analysis: Distribution by Type of Grant Application
Figure 7.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 7.8 Grant Analysis: Distribution by Activity Code
Figure 7.9 Grant Analysis: Distribution by Study Section Involved
Figure 7.10 Grant Analysis: Distribution by Type of Recipient Organization
Figure 7.11 Word Cloud Analysis: Emerging Focus Areas
Figure 7.12 Grant Analysis: Geographical Distribution of Recipient Organizations
Figure 7.13 Popular NIH Departments: Distribution by Number of Grants
Figure 7.14 Prominent Program Officers: Distribution by Number of Grants
Figure 7.15 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 8.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 8.6 Partnerships and Collaborations: Distribution by Focus Areas
Figure 8.7 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 8.8 Most Active Players: Distribution by Number of Partnerships
Figure 8.9 Partnerships and Collaborations: Regional Distribution
Figure 8.9.1 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investment
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Startup-Health Indexing: Publisher Analysis Perspective
Figure 9.8 Spider Web Analysis: Leading Companies
Figure 10.1 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
Figure 10.2 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
Figure 10.3 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
Figure 10.4 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
Figure 10.5 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
Figure 10.6 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
Figure 10.7 Therapeutic Vaccines Market in US, 2022-2035
Figure 10.8 Therapeutic Vaccines Market in Canada, 2022-2035
Figure 10.9 Therapeutic Vaccines Market in UK, 2022-2035
Figure 10.10 Therapeutic Vaccines Market in Germany, 2022-2035
Figure 10.11 Therapeutic Vaccines Market in France, 2022-2035
Figure 10.12 Therapeutic Vaccines Market in Italy, 2022-2035
Figure 10.13 Therapeutic Vaccines Market in Spain, 2022-2035
Figure 10.14 Therapeutic Vaccines Market in Australia, 2022-2035
Figure 10.15 Therapeutic Vaccines Market in Japan, 2022-2035
Figure 10.16 Therapeutic Vaccines Market in Korea, 2022-2035
Figure 10.17 Therapeutic Vaccines Market in Brazil, 2022-2035
Figure 10.18 Therapeutic Vaccines Market in Israel, 2022-2035
Figure 10.19 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.20 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 10.21 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
Figure 10.22 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Figure 10.23 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
Figure 10.24 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.25 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
Figure 10.26 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
Figure 10.27 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
Figure 10.28 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
Figure 10.29 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Figure 10.30 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Figure 10.31 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
Figure 10.32 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
Figure 10.33 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Figure 10.34 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
Figure 10.35 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
Figure 11.1 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Figure 11.2 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Figure 11.3 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Figure 11.4 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Figure 11.5 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Figure 11.6 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Figure 11.7 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 11.8 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Figure 12.1 Vaccine CMOs: Distribution by Year of Establishment
Figure 12.2 Vaccine CMOs: Distribution by Company Size and Geographical Location
Figure 12.3 World Map Representation: Distribution by Geography
Figure 12.4 Vaccine CMOs: Distribution by Types of Service(s) Offered
Figure 12.5 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Figure 12.6 Vaccine CMOs: Distribution by Scale of Operation
Figure 12.7 Vaccine CMOs: Distribution by Type of Expression System(s) Used
Figure 12.8 Vaccine CMOs: Distribution by Type of Vaccine Manufactured
Figure 13.1 Concluding Remarks: Overall Market Landscape
Figure 13.2 Concluding Remarks: Clinical Trial Analysis
Figure 13.3 Concluding Remarks: Academic Grant Analysis
Figure 13.4 Concluding Remarks: Partnerships and Collaborations
Figure 13.5 Concluding Remarks: Start-up Health Indexing
Figure 13.6 Concluding Remarks: Market Forecast
List of Tables
Table 3.1 Vaccines for Cancer Treatment
Table 3.2 Vaccines for HIV Treatment
Table 3.3 Vaccines for HPV Treatment
Table 3.4 Vaccines for Herpes Treatment
Table 4.1 List of Therapeutic Vaccines
Table 5.1 Global Therapeutic Vaccines: List of Companies Profiled
Table 5.2 BioNTech: Company Snapshot
Table 5.3 Vaccine Profile: BNT-111
Table 5.4 Vaccine Profile: BNT-112
Table 5.5 Vaccine Profile: BNT-113
Table 5.6 Vaccine Profile: BNT-115
Table 5.7 Vaccine Profile: BNT-116
Table 5.8 Vaccine Profile: BNT-122
Table 5.9 Vaccine Profile: W_pro1
Table 5.10 Vaccine Profile: HPV Vaccine
Table 5.11 Vaccine Profile: IVAC MUTANOME
Table 5.12 Vaccine Profile: RBL001/RBL002
Table 5.13 Vaccine Profile: NEO-PV-01
Table 5.14 BioNTech: Recent Developments and Future Outlook
Table 5.15 Brii Biosciences: Company Snapshot
Table 5.16 Vaccine Profile: Bri-179
Table 5.17 Vaccine Profile: Bri-835
Table 5.18 Vaccine Profile: Bri-778
Table 5.19 Vaccine Profile: Bri-732
Table 5.20 Vaccine Profile: Bri-296
Table 5.21 Brii Biosciences: Recent Developments and Future Outlook
Table 5.22 GlobeImmune: Company Snapshot
Table 5.23 Vaccine Profile: GI-6301
Table 5.24 Vaccine Profile: GI-6207
Table 5.25 Vaccine Profile: GI-4000
Table 5.26 Vaccine Profile: GS-4774
Table 5.27 Vaccine Profile: GI-5005
Table 5.28 GlobeImmune: Recent Developments and Future Outlook
Table 5.29 Immatics: Company Snapshot
Table 5.30 Vaccine Profile: APVAC
Table 5.31 Vaccine Profile: IMA901
Table 5.32 Vaccine Profile: IMA910
Table 5.33 Vaccine Profile: IMA950
Table 5.34 Vaccine Profile: IMA970A
Table 5.35 Immatics: Recent Developments and Future Outlook
Table 5.36 Immune Response Biopharma: Company Snapshot
Table 5.37 Vaccine Profile: IR103
Table 5.38 Vaccine Profile: REMUNE
Table 5.39 Vaccine Profile: NeuroVax
Table 5.40 Vaccine Profile: RAVAX
Table 5.41 Vaccine Profile: Zorcell
Table 5.42 Immune Response Biopharma: Recent Developments and Future Outlook
Table 5.43 Immunitor: Company Snapshot
Table 5.44 Vaccine Profile: Atherosclerosis Vaccine
Table 5.45 Vaccine Profile: V3-MOMMO
Table 5.46 Vaccine Profile: Hepcortespenlisimut-L
Table 5.47 Vaccine Profile: V-Boost
Table 5.48 Vaccine Profile: V3-OVA
Table 5.49 Vaccine Profile: V3-Myoma
Table 5.50 Vaccine Profile: V3-Cervix
Table 5.51 Vaccine Profile: V7
Table 5.52 Vaccine Profile: V3-X
Table 5.53 Vaccine Profile: V3-P
Table 5.54 Vaccine Profile: V-Endo
Table 5.55 Vaccine Profile: V8
Table 5.56 Vaccine Profile: V-SARS
Table 5.57 Immunitor: Recent Developments and Future Outlook
Table 5.58 Innovio Pharmaceuticals: Company Snapshot
Table 5.59 Vaccine Profile: VGX-3100
Table 5.60 Vaccine Profile: INO-3107
Table 5.61 Vaccine Profile: INO-5401
Table 5.62 Vaccine Profile: INO-5151
Table 5.63 Vaccine Profile: INO-3112
Table 5.64 Vaccine Profile: INO-5150
Table 5.65 Vaccine Profile: INO-3106
Table 5.66 Vaccine Profile: INO-1800
Table 5.67 Innovio Pharmaceuticals: Recent Developments and Future Outlook
Table 5.68 Moderna: Company Snapshot
Table 5.69 Vaccine Profile: mRNA-4157
Table 5.70 Vaccine Profile: mRNA-3927
Table 5.71 Vaccine Profile: mRNA-3705
Table 5.72 Vaccine Profile: mRNA-3745
Table 5.73 Vaccine Profile: mRNA-5671
Table 5.74 Vaccine Profile: mRNA-2752
Table 5.75 Moderna: Recent Developments and Future Outlook
Table 8.1 Global Therapeutic Vaccines: List of Partnerships and Collaborations, 2016-2022
Table 9.1 Therapeutic Vaccines Start-ups: Distribution by Location of Headquarters
Table 10.1 Global Therapeutic Vaccines: Summary of the Competitive Insights
Table 11.1 List of Marketed Preventive Vaccines
Table 11.2 List of Clinical-Stage Preventive Vaccines
Table 12.1 Vaccine Contract Manufacturers: List of Service Providers
Table 12.2 Vaccine CMOs: Information on Type of Service(s) Offered
Table 12.3 Vaccine CMOs: Information on Scale of Operation
Table 12.4 Vaccine CMOs: Information on Type of Expression System(s) Used
Table 12.5 Vaccine CMOs: Information on Type of Vaccines Manufactured
Table 14.1 Therapeutic Vaccines: Distribution by Phase of Development
Table 14.2 Therapeutic Vaccines: Distribution by Type of Vaccine
Table 14.3 Therapeutic Vaccines: Distribution by Type of Vaccine (by Method of Composition)
Table 14.4 Therapeutic Vaccines: Distribution by Type of Therapy
Table 14.5 Therapeutic Vaccines: Distribution by Target Disease Indication
Table 14.6 Therapeutic Vaccines: Distribution by Route of Administration
Table 14.7 Therapeutic Vaccines: Distribution by Dosage
Table 14.8 Therapeutic Vaccines Developers: Distribution by Type of Developers
Table 14.9 Therapeutic Vaccines Developers: Distribution by Year of Establishment
Table 14.10 Therapeutic Vaccines Developers: Distribution by Company Size
Table 14.11 Therapeutic Vaccines Developers: Distribution by Location of Headquarters
Table 14.12 Leading Developers
Table 14.13 Grid Analysis: Distribution by Phase of Development, Company Size and Location of Headquarters
Table 14.14 BioNTech: Annual Revenues, 2016-2021 (USD Million)
Table 14.15 Brii Biosciences: Annual Revenues, 2016-2021 (USD Million)
Table 14.16 GlobeImmune: Annual Revenues, 2016-2021 (USD Million)
Table 14.17 Immatics: Annual Revenues, 2016-2021 (USD Million)
Table 14.18 Immune Response Biopharma: Annual Revenues, 2016-2021 (USD Million)
Table 14.19 Inovio Pharmaceuticals: Annual Revenues, 2016-2021 (USD Million)
Table 14.20 Moderna: Annual Revenues, 2016-2021 (USD Million)
Table 14.21 Clinical Trial Analysis: Scope and Methodology
Table 14.22 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2010-2022
Table 14.23 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2010-2022
Table 14.24 Clinical Trial Analysis: Distribution by Trial Phase
Table 14.25 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.26 Clinical Trial Analysis: Cumulative Year-wise Trend by Trial Recruitment Status
Table 14.27 Clinical Trial Analysis: Distribution by Study Design
Table 14.28 Clinical Trial Analysis: Distribution by Trial Focus Area
Table 14.29 Clinical Trial Analysis: Distribution by Target Disease Indication
Table 14.30 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.31 Most Active Players: Distribution by Number of Registered Trials
Table 14.32 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Table 14.33 Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 14.34 Grant Analysis: Cumulative Year-wise Trend, 2016-2022
Table 14.35 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million) 2016-2022
Table 14.36 Grant Analysis: Distribution by Administering Institute Center
Table 14.37 Grant Analysis: Distribution by Support Period
Table 14.38 Grant Analysis: Distribution by Administering Institute Center and Support Period
Table 14.39 Grant Analysis: Distribution by Type of Grant Application
Table 14.40 Grant Analysis: Distribution by Purpose of Grant Award
Table 14.41 Grant Analysis: Distribution by Activity Code
Table 14.42 Grant Analysis: Distribution by Study Section Involved
Table 14.43 Grant Analysis: Distribution by Type of Recipient Organization
Table 14.44 Grant Analysis: Geographical Distribution of Recipient Organizations
Table 14.45 Popular NIH Departments: Distribution by Number of Grants
Table 14.46 Prominent Program Officers: Distribution by Number of Grants
Table 14.47 Popular Recipient Organizations: Distribution by Number of Grants
Table 14.48 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 14.49 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.50 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 14.51 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.52 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.53 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 14.54 Most Active Players: Distribution by Number of Partnerships
Table 14.55 Partnerships and Collaborations: Regional Distribution
Table 14.56 Startup-Health Indexing: Distribution by Location of Headquarters
Table 14.57 Startup-Health Indexing: Distribution by Supplier Strength
Table 14.58 Startup-Health Indexing: Distribution by Pipeline Strength
Table 14.59 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 14.60 Startup-Health Indexing: Distribution by Financial Investment
Table 14.61 Startup-Health Indexing: Distribution by Partnership Activity
Table 14.62 Startup-Health Indexing: Publisher Analysis Perspective
Table 14.63 Global Therapeutic Vaccines Market, 2022-2035 (USD Million)
Table 14.64 Global Therapeutic Vaccines Market: Distribution by Type of Vaccine, 2022-2035
Table 14.65 Global Therapeutic Vaccines Market: Distribution by Method of Vaccine Composition, 2022-2035
Table 14.66 Global Therapeutic Vaccines Market: Distribution by Type of Therapy, 2022-2035
Table 14.67 Global Therapeutic Vaccines Market: Distribution by Target Disease Indication, 2022-2035
Table 14.68 Global Therapeutic Vaccines Market: Distribution by Route of Administration, 2022-2035
Table 14.69 Therapeutic Vaccines Market in US, 2022-2035
Table 14.70 Therapeutic Vaccines Market in Canada, 2022-2035
Table 14.71 Therapeutic Vaccines Market in UK, 2022-2035
Table 14.72 Therapeutic Vaccines Market in Germany, 2022-2035
Table 14.73 Therapeutic Vaccines Market in France, 2022-2035
Table 14.74 Therapeutic Vaccines Market in Italy, 2022-2035
Table 14.75 Therapeutic Vaccines Market in Spain, 2022-2035
Table 14.76 Therapeutic Vaccines Market in Australia, 2022-2035
Table 14.77 Therapeutic Vaccines Market in Japan, 2022-2035
Table 14.78 Therapeutic Vaccines Market in Korea, 2022-2035
Table 14.79 Therapeutic Vaccines Market in Brazil, 2022-2035
Table 14.80 Therapeutic Vaccines Market in Israel, 2022-2035
Table 14.81 ASP0113 (Astellas Pharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.82 Copaxone (Teva Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Table 14.83 Galinpeptimut-S (Sellas Life Sciences): Estimated Sales, 2024-2035 (USD Million)
Table 14.84 Hepcortespenlisimut-L (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Table 14.85 ICT-107 (Precision Life Sciences): Estimated Sales, 2022-2035 (USD Million)
Table 14.86 IR103 (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.87 MGN1703 (Mologen): Estimated Sales, 2022-2035 (USD Million)
Table 14.88 Neuronata-R (OptiNose): Estimated Sales, 2027-2035 (USD Million)
Table 14.89 OncoVax (Corestem): Estimated Sales, 2023-2035 (USD Million)
Table 14.90 OSE2101 (OSE Immunotherapeutics): Estimated Sales, 2022-2035 (USD Million)
Table 14.91 Provenge (Dendreon Pharmaceuticals): Estimated Sales, 2022-2035 (USD Million)
Table 14.92 REMUNE (Immune Response Biopharma): Estimated Sales, 2022-2035 (USD Million)
Table 14.93 RIAVAX (Kael-GemVax): Estimated Sales, 2024-2035 (USD Million)
Table 14.94 V503 (Merck): Estimated Sales, 2027-2035 (USD Million)
Table 14.95 V7 (Immunitor): Estimated Sales, 2022-2035 (USD Million)
Table 14.96 VGX-3100 (Inovio Pharmaceuticals): Estimated Sales, 2023-2035 (USD Million)
Table 14.97 Vigil (Gradalis): Estimated Sales, 2025-2035 (USD Million)
Table 14.98 Clinical-Stage Preventive Vaccines: Distribution by Phase of Development
Table 14.99 Clinical-Stage Preventive Vaccines: Distribution by Route of Administration
Table 14.100 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API
Table 14.101 Clinical-Stage Preventive Vaccines: Distribution by Type of Vaccine API and Phase of Development
Table 14.102 Clinical-Stage Preventive Vaccines: Distribution by Dosage Form
Table 14.103 Clinical-Stage Preventive Vaccines: Distribution by Target Disease Indication
Table 14.104 Key Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.105 Key Non-Industry Players: Distribution by Number of Vaccines in Clinical Development
Table 14.106 Vaccine CMOs: Distribution by Year of Establishment
Table 14.107 Vaccine CMOs: Distribution by Company Size and Geographical Location
Table 14.108 Vaccine CMOs: Distribution by Types of Service(s) Offered
Table 14.109 Vaccine CMOs: Distribution by Additional Services Offered and Location of Headquarters
Table 14.110 Vaccine CMOs: Distribution by Scale of Operation
Table 14.111 Vaccine CMOs: Distribution by Type of Expression System(s) Used
Table 14.112 Vaccine CMOs: Distribution by Type of Vaccine Manufactured

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • 3D Medicines
  • Abivax
  • AC Immune
  • Adaptive Biotechnologies
  • Aduro Biotech
  • Advaxis
  • AFFiRiS 
  • Altimmune
  • ApolloBio
  • Arbutus Biopharma
  • Archivel Farma 
  • Argos Therapeutics
  • Astellas Pharma
  • Aston Sci.
  • AstraZeneca
  • AVAX Technologies
  • Axon Neuroscience
  • Bavarian Nordic
  • Beijing Genomics Institute
  • Bellicum Pharmaceuticals
  • Bionor Immuno
  • BioNTech
  • Biosantech
  • Brii Biosciences
  • Bristol Myers Squibb
  • Cancer Insight
  • Cancer Vaccines
  • Chinook Therapeutics 
  • Chongqing Jiachen Biotechnology
  • Corestem
  • CuraVac
  • Cure&Sure Biotech
  • CureVac
  • CYTLIMIC 
  • Dana-Farber Cancer Institute
  • DCPrime
  • Dendreon Pharmaceuticals
  • Dynavax Technologies
  • EMD Serono
  • Enterome
  • Epimmune
  • eTheRNA immunotherapies
  • European Oncology Clinical Trial Group
  • European Network of Gynaecological Oncological Trial Groups (ENGOT) 
  • FIT Biotech
  • Frame Therapeutics
  • Frontier Biotechnologies 
  • Galena Biopharma
  • GeneCure Biotechnologies
  • Genentech
  • Geneos Therapeutics
  • Genexine
  • Genocea Biosciences
  • Genticel
  • Gilead Sciences
  • GlaxoSmithKline
  • GlobeImmune
  • Gradalis
  • Gritstone bio
  • Hangzhou Neoantigen Therapeutics
  • Helocyte
  • Ichor Medical Systems
  • Immatics Biotechnologies
  • Immune Design
  • Immune Response BioPharma
  • Immunicum
  • Immunitor
  • ImmunityBio
  • ImmunoCellular Therapeutics
  • Immunomic Therapeutics
  • Immunor
  • ImmunoVaccine Technologies
  • Immunovative Therapies
  • ImmusanT
  • Immutep
  • Incyte
  • InnaVirVax
  • Inovio Pharmaceuticals
  • Invectys
  • iOncologi
  • ISA Pharmaceuticals
  • Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson)
  • Janssen Vaccines & Prevention (a subsidiary of Johnson & Johnson)
  • GemVax & KAEL
  • Kun Tuo
  • Laboratorios Silanes
  • LG Life Sciences
  • Eli Lilly 
  • MabVax Therapeutics
  • Madison Vaccines
  • Marker Therapeutics
  • Medigene
  • MedImmune
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Ministry of Health and Family Welfare (MoHFW)
  • Moderna
  • MOLOGEN
  • Morphogenesis
  • Mymetics 
  • NantBioScience (a subsidiary of NantWorks)
  • National Heart, Lung, and Blood Institute (NHLBI)
  • NEC OncoImmunity
  • Nektar Therapeutics
  • NewLink Genetics
  • Nobelpharma
  • Nordic Society of Gynaecological Oncology (NSGO)
  • Nouscom
  • Novartis Pharmaceuticals
  • NovaRx 
  • NuGenerex Immuno-Oncology
  • Nykode Therapeutics
  • OncBioMune Pharmaceuticals
  • OncoPep
  • OncoTherapy Science
  • Origimm Biotechnology (acquired by Sanofi)
  • OSE Immunotherapeutics
  • Oxford Vacmedix
  • PapiVax Biotech
  • Parker Institute for Cancer Immunotherapy
  • PCI Biotech 
  • PDC*line Pharma
  • Peptinov
  • Pfizer
  • Precision BioSciences 
  • Precision Life Sciences
  • Profectus BioSciences
  • QIAGEN
  • Quantoom Biosciences
  • Regeneron Pharmaceuticals
  • ReiThera
  • Replicate Bioscience
  • RhoVac
  • Rigontec (acquired by Merck)
  • ROVI Pharmaceuticals
  • Sanofi 
  • SciVac Therapeutics 
  • Selecta Biosciences
  • SELLAS Life Sciences
  • Shenzhen BioScien Pharmaceuticals 
  • Stemirna Therapeutics
  • Stemline Therapeutics
  • Teva Pharmaceuticals
  • Themis Medicare
  • Thyas
  • Translate Bio (acquired by Sanofi)
  • UConn Health
  • Ultimovacs
  • University of Oxford 
  • University of Pennsylvania
  • Vaccinogen
  • Vaccitech
  • VaxEquity
  • VAXIMM
  • Vaxine
  • VAXON Biotech
  • VBI Vaccines
  • Vertex
  • Vical
  • ViciniVax
  • Wistar Institute
  • XEME Biopharma

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2024-2032 - Product Image

Therapeutic Vaccines Market Report by Type, Disease Type, Technology, Distribution Channel, and Region 2024-2032

  • Report
  • 147 Pages
  • Global
From
Therapeutic Vaccines Market by Vaccines Type, Disease Indication, Administration, End-User - Global Forecast 2025-2030 - Product Image

Therapeutic Vaccines Market by Vaccines Type, Disease Indication, Administration, End-User - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Therapeutic Vaccines - Global Strategic Business Report - Product Image

Therapeutic Vaccines - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Vaccine Vials Market by Report Type (Multi Dose, Single Dose), Material (Glass, Polymer), Capacity (10ml, 20ml, 2ml, 3ml, 5ml), Application (Preventive Vaccine, Therapeutic Vaccine), and Region 2024-2032 - Product Image

Vaccine Vials Market by Report Type (Multi Dose, Single Dose), Material (Glass, Polymer), Capacity (10ml, 20ml, 2ml, 3ml, 5ml), Application (Preventive Vaccine, Therapeutic Vaccine), and Region 2024-2032

  • Report
  • 146 Pages
  • Global
From
Therapeutic Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type - Product Image

Therapeutic Vaccine Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Product Type

  • Report
  • 83 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.